Evidence map›Paper›PMID 28640204›Full record

ArticleMarine drugs2017

Fucoidan Does Not Exert Anti-Tumorigenic Effects on Uveal Melanoma Cell Lines.

Michaela Dithmer, Anna-Maria Kirsch, Elisabeth Richert, Sabine Fuchs, Fanlu Wang, Harald Schmidt, Sarah E Coupland, Johann Roider, Alexa Klettner

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
6.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Fucoidan fromMarine drugs · 2026
    Article
  2. Article
  3. Effects of Fucoidans on Activated Retinal Microglia.International journal of molecular sciences · 2024
    Article
  4. Review
  5. Comparison of Fucoidans fromInternational journal of molecular sciences · 2023
    Article
  6. Article
  7. Interaction of High-Molecular Weight Fucoidan fromInternational journal of molecular sciences · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Effects of CrudeMarine drugs · 2019
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Michaela DithmerDepartment of Ophthalmology, University of Kiel, University Medical Center, Arnold-Heller-Str. 3, 24105 Kiel, Germany. michaela_dithmer@web.de.
Anna-Maria KirschDepartment of Ophthalmology, University of Kiel, University Medical Center, Arnold-Heller-Str. 3, 24105 Kiel, Germany. anna.maria.kirsch@gmx.de.
Elisabeth RichertDepartment of Ophthalmology, University of Kiel, University Medical Center, Arnold-Heller-Str. 3, 24105 Kiel, Germany. elisabeth.richert@uksh.de.
Sabine FuchsExperimental Trauma Surgery, University of Kiel, University Medical Center, Arnold-Heller-Str. 3, 24105 Kiel, Germany. sabine.fuchs@uksh.de.
Fanlu WangExperimental Trauma Surgery, University of Kiel, University Medical Center, Arnold-Heller-Str. 3, 24105 Kiel, Germany. fanlu.wang@uksh.de.
Harald SchmidtMetaPhysiol, Am Römerberg, 55270 Essenheim, Germany. schmidt@metaphysiol.de.
Sarah E CouplandDepartment of Molecular and Clinical Cancer Medicine, Liverpool Ocular Oncology Research Group, Pathology, University of Liverpool, Liverpool L69 3BX, UK. s.e.coupland@liverpool.ac.uk.
Johann RoiderDepartment of Ophthalmology, University of Kiel, University Medical Center, Arnold-Heller-Str. 3, 24105 Kiel, Germany. johann.roider@uksh.de.
Alexa KlettnerDepartment of Ophthalmology, University of Kiel, University Medical Center, Arnold-Heller-Str. 3, 24105 Kiel, Germany. aklettner@auge.uni-kiel.de.
Kiel University · DEUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe polysaccharide fucoidan is widely investigated as an anti-cancer agent. Here, we tested the effect of fucoidan on uveal melanoma cell lines.

methodsThe effect of 100 µM fucoidan was investigated on five cell lines (92.1, Mel270 OMM1, OMM2.3, OMM2.5) and of 1 µg/mL-1 mg/mL fucoidan in two cell lines (OMM1, OMM2.3). Cell proliferation and viability were investigated with a WST-1 assay, migration in a wound healing (scratch) assay. Vascular Endothelial Growth Factor (VEGF) was measured in ELISA. Angiogenesis was evaluated in co-cultures with endothelial cells. Cell toxicity was induced by hydrogen-peroxide. Protein expression (Akt, ERK1/2, Bcl-2, Bax) was investigated in Western blot.

resultsFucoidan increased proliferation in two and reduced it in one cell line. Migration was reduced in three cell lines. The effect of fucoidan on VEGF was cell type and concentration dependent. In endothelial co-culture with 92.1, fucoidan significantly increased tubular structures. Moreover, fucoidan significantly protected all tested uveal melanoma cell lines from hydrogen-peroxide induced cell death. Under oxidative stress, fucoidan did not alter the expression of Bcl-2, Bax or ERK1/2, while inducing Akt expression in 92.1 cells but not in any other cell line.

conclusionFucoidan did not show anti-tumorigenic effects but displayed protective and pro-angiogenic properties, rendering fucoidan unsuitable as a potential new drug for the treatment of uveal melanoma.

Indexed as

Antineoplastic AgentsBlotting, WesternCell Line, TumorCell ProliferationCell SurvivalCoculture TechniquesDose-Response Relationship, DrugEnzyme-Linked Immunosorbent AssayGene Expression Regulation, NeoplasticHumansMelanomaNeovascularization, PathologicOxidative StressPolysaccharidesUveal MelanomaUveal NeoplasmsAntineoplastic AgentsfucoidanPolysaccharidesVascular Endothelial Growth Factor Aangiogenesisfucoidanoxidative stressuveal melanomaVEGF

Identifiers

PMID28640204
PMCPMC5532635
OpenAlexW2651045997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.